On Tuesday, Valneva SE VALN reported Part 3 information in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, Ixchiq.
The vaccine confirmed a sustained 98.3% sero-response price one yr after the one vaccination.
These outcomes assist and strengthen the pivotal information beforehand reported for adolescents (12 to 17 years previous), which supported submitting for potential label extension to this age group within the U.S., Europe, and Canada.
Additionally Learn: Valneva’s Chikungunya Shot Exhibits Robust, Lengthy-Lasting Antibody Persistence At Three Years, Comparable In Older And Youthful Adults
Knowledge from this trial are additionally anticipated to assist the licensure of Ixchiq in Brazil. It will be the primary potential approval to be used in endemic populations.
The one-year VLA1553-321 information confirmed {that a} single-dose vaccination induced a excessive, sustained immune response in an immunogenicity subset of contributors who had been CHIKV adverse at baseline, with a seroresponse price of 98.3% (232 out of 236 contributors) one yr after vaccination (Day 360) in comparison with 99.1% (232 out of 234 contributors) after six month3 (Day 180) and 98.8% (248 out of 251 contributors) 28 days after vaccination.
The outcomes complement the long-term persistence information beforehand reported for adults. Additionally they verify a robust and long-lasting antibody response to the vaccine.
Moreover, the one-year information confirmed {that a} single dose of the vaccine was typically nicely tolerated in adolescents.
All through the trial, an Impartial Knowledge Security Monitoring Board (IDSMB) constantly assessed security information and located no issues of safety.
The vaccine is at present authorized within the U.S., Europe, and Canada to forestall illness attributable to the chikungunya virus in people 18 and older.
Along with Brazil, Valneva expects to obtain advertising approval in the UK within the first quarter of the yr.
Worth Motion: Valneva inventory is 9.84% at $4.80 throughout the premarket session finally test Tuesday.
Learn Subsequent:
Market Information and Knowledge dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
